GRI BIO Files 8-K: Confirms Emerging Growth Status, Updates Contact Info

Ticker: GRI · Form: 8-K · Filed: Jan 16, 2024 · CIK: 1824293

Gri Bio, INC. 8-K Filing Summary
FieldDetail
CompanyGri Bio, INC. (GRI)
Form Type8-K
Filed DateJan 16, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: administrative, corporate-governance, regulatory-filing

TL;DR

**GRI BIO filed an 8-K updating contact info and confirming emerging growth status, mostly administrative.**

AI Summary

GRI BIO, Inc. filed an 8-K on January 16, 2024, primarily to update its corporate information and confirm its status as an emerging growth company. The filing lists the company's current business address as 2223 Avenida de la Playa, #208, La Jolla, CA 92037, and its telephone number as (619) 400-1170. This matters to investors because it provides updated administrative details and confirms the company's regulatory status, which can impact reporting requirements and investor perception.

Why It Matters

This filing provides updated administrative details for GRI BIO, Inc., including its current address and phone number, and confirms its status as an emerging growth company, which affects its regulatory compliance and reporting obligations.

Risk Assessment

Risk Level: low — This 8-K filing is purely administrative, updating contact information and confirming regulatory status, with no material financial or operational changes.

Analyst Insight

This filing is administrative and does not contain information that would warrant immediate investment action. Investors should note the updated contact details and the company's emerging growth status, but look for more substantive filings for investment decisions.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant as specified in its charter is GRI BIO, INC.

What is the current business address and telephone number of GRI BIO, Inc. as reported in this filing?

The current business address is 2223 Avenida de la Playa, #208, La Jolla, CA 92037, and the telephone number is (619) 400-1170.

What was the former name of GRI BIO, Inc. and when did the name change occur?

The former name was Vallon Pharmaceuticals, Inc., and the date of name change was 20200910.

Is GRI BIO, Inc. an emerging growth company according to this 8-K filing?

Yes, GRI BIO, Inc. has indicated by check mark that it is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

On which exchange is GRI BIO, Inc.'s Common Stock registered and what is its trading symbol?

GRI BIO, Inc.'s Common Stock, with a par value of $0.0001 per share, is registered on The Nasdaq Capital Market under the trading symbol GRI.

Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-01-16 08:45:50

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On January 16, 2024, GRI Bio, Inc. (the "Company"), posted a Virtual Investor CEO Corner event video with the Company's Chief Executive Officer, Dr. W. Marc Hertz. A link to the video may be found at https://www.virtualinvestorco.com/ceo-corner-gri-011624 and is incorporated by reference herein. In addition, on January 16, 2024, the Company posted an updated corporate presentation on its website www.gribio.com. A copy of the presentation is attached as Exhibit 99.1 to this report and is incorporated by reference herein The information in this Item 7.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 GRI Bio, Inc. Corporate Presentation, dated January 16, 2024.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 16, 2024 GRI BIO, INC. By: /s/ Leanne Kelly Name: Leanne Kelly Title Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing